

INDEX

A

Accidents. *See* Radiation accidents
Acetylcholine, 147–148
Acute radiation syndrome. *See also* Radiation injuries
 clinical aspects of the U.S. criticality experience, 22–25
 effect of clinical support on LD₅₀ dose effect curve, 22
 gastrointestinal subsyndrome, 20–21, 244–245
 hematopoietic subsyndrome, 19–20, 62–63, 243–244
 incidence of nausea and emesis as function of dose, 19
 influence of trauma on LD₅₀, 21–22
 medical issues in patient management, 27–28
 multiorgan failure, 18, 245–246
 neurovascular subsyndrome, 21, 245
 overview, 14
 pathophysiology, 19–21
 radiation doses resulting in classic syndromes, 45
 radiation lethality curve, 21
 research aspects, 29–30
 supportive care, 27
 survivability related to dosage, 103–104
 treatment of, 25–27
 whole-body radiation dose-effect relationship, 44
Adult/Pediatric Field Medical Record, 104, 119
AFRRI. *See* Armed Forces Radiobiology Research Institute
AFRRI *Pocket Guide: Emergency Radiation Medicine Response*, 106
Al Qaeda, 173
ALARA. *See* As low as reasonable achievable concept
Alpha particles, 219
Americium-241, 11
Aminoglycosides, 92
Aminothiols, 250–251
Animal studies, 136–139, 205–206
Antiapoptotic mechanisms, 248–249
Antiemetics, 149
Antimicrobial agents
 aminoglycosides, 92
 available agents for managing infections after irradiation,
 91–94
 biological response modifiers, 93–94
 carbapenems, 92
 cephalosporins, 92
 clindamycin, 92
 delivery of, 91, 94
 doses of, 90–91
 immunomodulating agents, 93–94
 intramuscular administration, 91
 intravenous administration, 91
 metronidazole, 92
 oral administration, 91
 oxazolidinones, 93
 penicillins, 92
 quinolones, 92
 selection of, 90
 streptogramins, 93
 subcutaneous administration, 91
 synergistic combinations of, 93
 topical administration, 91
 vaccines, 94–95
 vancomycin, 92–93
Antioxidants, 251–252
Armed Forces Radiobiology Research Institute, 18, 28, 29, 61,
 104–105, 119–120
ARS. *See* Acute radiation syndrome
As low as reasonably achievable concept, 221–222

Auditory function
 radiation effects, 138

B

Bacterial infections. *See also* Infections
 combined therapy, 94
 endogenous, 87–88
 etiology of, 86–89
 exogenous, 88–89
 immunomodulators, 94
 overview, 84–85
 polymicrobial, 88
 prophylactic methods for prevention, 89
 sepsis, 87–88
 therapeutic agents, 90–94
 treatment recommendations for military use or national disasters,
 94–95
BAT. *See* Biodosimetry Assessment Tool
Behavioral radiation effects
 clinical irradiation and, 130–131
 idealized performance time-course profiles, 133
 predicting changes in military performance, 131–133
 radiation accidents and, 129–130
 responses following exposure, 132
Beta particles, 219
BIER VIII. *See* Biological Effects of Ionizing Radiation
Binding energy, 3
Bioassays, radiation, 102
Biodosimetry. *See* Biological dosimetry; Cytogenetic biodosimetry
Biodosimetry Assessment Tool, 28, 61, 105
Biodosimetry Worksheet, 104–105, 120–124
Biological dosimetry. *See also* Cytogenetic biodosimetry; Radiation
 dose
 acute-phase assessment methods, 114–115
 based on acute photon-equivalent exposures, 108
 blood-based biomarkers, 111–112
 candidate radiation biomarkers, 110–111
 cytogenetic biodosimetry, 112–113
 field medical record, 119
 functional tests from tissue system and organs, 110–111
 grading system, 125
 guidance for early-phase response, 104
 hematologic biomarkers, 111–112
 hematological bioindicators, 107–109
 internal contamination and, 106–107
 medical recording, 104–106
 metabolomic biomarkers, 111–112
 overview, 102–104
 prodromal signs and symptoms, 107
 proteomic biomarkers, 111–112
 radiation-responsive biomarkers, 111–112
 retrospective, 276
 triage diagnostic approaches, 109–112
 worksheet, 120–124
Biological Effects of Ionizing Radiation, 54
Biological response modifiers, 93–94, 253–255
Blast effects
 direct blast wave peak overpressure, 41–42
 indirect blast wind force, 42
 of nuclear weapons, 5–7, 41–42
Blocking agents, 77
Blood-based biomarkers, 111–112
Bone cancer, 205
Bone marrow transplants, 149

- Brain injuries
 - animal studies, 136
 - inflammation, 148–149
 - neurochemistry, 147–148
 - neurophysiological changes in the hippocampus following radiation, 139–145
 - radiation-induced, 133–134
 - radiation-induced hyperexcitability, 144
- Breaks, chromosome, 271–272
- Breast cancer, 204
- Bremsstrahlung, 5
- Burn beds, 59
- Burn injuries
 - ionizing radiation and, 199–201
 - nuclear weapons and, 7–8

C

- Carbapenems, 92
- Carcinogenesis, 201–205
- Cataract formation, 198
- CBRN. *See* Chemical, biological, radiological, and nuclear agents
- Cellular models, 146–147
- Centers for Disease Control and Prevention, 28
- Central nervous system
 - latent radiation damage, 134–135
 - radiation biomarkers and functional tests, 110–111
 - radiation damage, 139–142
 - radiogenic pathology, 145–146
 - space radiation exposure, 142–144
- Cephalosporins, 92
- Cerebrovascular system
 - radiation biomarkers and functional tests, 110–111
- Cesium-137
 - effects on hippocampus function, 140–141
 - half-life and activity, 11
- Chelating agents, 77–79
- Chemical, biological, radiological, and nuclear agents
 - long-term health risks, 54
 - personal protection, 53–54
- Chernobyl nuclear reactor accident, 12–13, 130, 183, 224–225
- Chromosome-aberration bioassays, 62, 112–115
- Chromosome aberrations, 271–272
- Chromosome structure, 270–271
- Civilian personnel
 - personal protection, 54
 - psychological effects, 66–67
- Clindamycin, 92
- Clinical irradiation, 128, 130–131
- Cobalt-60, 11
- Cognitive performance, 138–139
- Colony stimulating factors, 25–26, 63
- Combined injuries
 - emergency treatment, 62
 - nuclear weapons and, 14
 - triage, 57–59
- Contamination surveys, 228–230
- Control zones, 230
- Conventional-injury triage, 55–57
- Countermeasures. *See* Radiation protection
- CSFs. *See* Colony stimulating factors
- Curie, 43
- Cutaneous syndrome, 64
- Cutaneous system
 - biodosimetry grading system, 125
 - erythema, 200
 - necrosis, 200
 - radiation biomarkers and functional tests, 110–111

- skin cancer, 200
 - skin damage, 199–201
 - transepithelial injuries, 200
 - ulceration, 200
- Cyclic adenosine monophosphate, 148
 - Cytogenetic biodosimetry. *See also* Biological dosimetry
 - acute high-dose exposures, 276
 - acute low-dose exposures, 276
 - assay harmonization, 273
 - blood sampling, culturing and analysis, 272
 - characteristics of ideal biodosimeter, 268
 - comparison of assays, 112–113
 - by dicentric assay, 272–276
 - dose assessment, 272–273
 - information management, 274–275
 - laboratory automation, 274–275
 - principles of, 268–272
 - quality control and assurance, 273
 - retrospective biological dosimetry, 276
 - statistical considerations, 273
 - treatment implications, 276–277
 - triage dose prediction, 275–276
 - Cytogenetic studies, 62
 - Cytokine therapy, 26
 - Cytokines, 253–255

D

- Decontamination
 - external, 65–66
 - initial management, 65
 - internal, 66
 - sites, 233–235
- Defense Nuclear Agency, 131
- Delayed, immediate, minimal, expectant triage system, 54–55
- Dicentric assays, 272–276
- Diluting agents, 77
- DIME triage system, 54–55
- Dirty bombs. *See* Radiological dispersal devices
- DNA response, 146, 242
- Dopamine, 147
- Dosage. *See* Radiation dose
- Dosimeters, 43, 186, 226–227, 231
- Dosimetry. *See* Biological dosimetry; Cytogenetic biodosimetry
- DTRA. *See* Defense Nuclear Agency

E

- Early performance decrements, 129, 137, 139
- Early transient incapacitation, 129, 133, 139
- Eicosanoids, 252–253
- Electromagnetic radiation, 218
- Electron paramagnetic resonance, 102, 109
- Electronic personal dosimeters, 226–227, 232
- Electrophysiology
 - neurophysiological outputs, 142
- Embryo preimplantation stage, 205, 206
- Emergency medical technicians, 233–236
- Emergency response personnel
 - long-term health risks, 54
 - personal protection, 53–54
 - psychological issues, 180–181
 - radiation dosage, 230–232
- Emergency treatment, 62
- Emesis
 - incidence as function of radiation dose, 19
- EMT. *See* Emergency medical technicians
- Endogenous antioxidant systems, 251–252
- Endogenous bacterial infections, 87–88

Enhanced radiation weapons, 4–5
 EPA. *See* U.S. Environmental Protection Agency
 EPDs. *See* Early performance decrements; Electronic personal dosimeters
 EPR. *See* Electron paramagnetic resonance
 ERW. *See* Enhanced radiation weapons
 Erythema
 body location record, 106
 skin erythema dose, 200
 ETI. *See* Early transient incapacitation
 Evacuation assets, 59
 Evacuation shadow, 178
 Exogenous bacterial infections, 88–89
 External decontamination, 65–66
 Extra cellular matrix, 198–199
 Eye injuries, 8

F

Fallout, 8–10
 FDA. *See* U.S. Food and Drug Administration
 Female sterility, 199
 Fetal studies, 206
 Field medical treatment facilities, 235–236
 First-Responder Radiological Assessment Triage, 105, 106
 Flame burns, 7, 42
 Flash burns, 7, 42
 FRAT. *See* First-Responder Radiological Assessment Triage
 Fukushima Daiichi, Japan incident, 224
 Fungal infections, 89
 Fusion weapons, 4

G

Gamma rays, 219
 Gastrointestinal syndrome, 20–21, 244–245
 Gastrointestinal system
 biodosimetry grading system, 125
 radiation biomarkers and functional tests, 110–111
 Geiger-Müller counters, 43, 76, 226, 236
 Genetic radiation effects, 208
 Genetic repair, 248
 Goiânia, Brazil incident, 178, 180
 Granulocyte-colony-stimulating factor, 26, 63
 Granulocyte-macrophage-colony-stimulating factor, 26, 63
 Growth retardation, 207
 Gun-assembled devices, 4
 Gustatory function, 138

H

Healthcare personnel
 assessing radionuclide contamination, 75–76
 personal protection, 54
 resupply under austere conditions, 59–60
 Helping behavior, 176–177
 Hematological bioindicators, 107–109, 111
 Hematopoietic growth factors, 63
 Hematopoietic stem cells, 209–210
 Hematopoietic syndrome, 19–20, 62–63, 243–244
 Hematopoietic system
 biodosimetry grading system, 125
 radiation biomarkers and functional tests, 110–111
 High-efficiency particulate air filters, 231
 Higher level medical treatment facilities, 236
 Hippocampus
 neurophysiological changes following radiation, 139–145
 radiation injuries, 136
 Hiroshima, Japan

casualty rate from day 1 to 4 months after detonation, 50
 causes of death, 48–49
 destruction patterns after nuclear detonation, 45–46
 distance from detonation and casualties, 47–48
 shielding factor, 47–48
 urban casualty patterns after nuclear detonation, 45–51
 zonal casualty rates four months after detonation, 46, 50

Histamine, 148
 Human karyotype, 270
 Hydrogen transfer, 247–248
 Hydrogen weapons, 4
 5-Hydroxytryptamine, 147
 Hyperexcitability, radiation-induced, 144
 Hypoxia, 246–247

I

Immunomodulators, 93–94, 253–255
 Immunosuppression, 209–210
 Implosion devices, 4
 Improvised nuclear devices, 41, 173–174
 In utero radiation effects, 205–208
 In-vivo studies, 205–206
 Infections. *See also* Bacterial infections
 fungal, 89
 radiation injury complications, 63–64
 viral, 89
 Inflammation response, 148–149
 Initial radiation, 8
 Interagency Modeling and Atmospheric Advisory Center, 230
 Interchanges, chromosome, 271
 Internal decontamination, 66
 International Atomic Energy Agency, 104
 International Commission on Radiological Protection, 198
 Intrachanges, chromosome, 271–272
 Iodine-131, 11
 Ion chambers, 226
 Ionizing radiation. *See also* Radiation
 background radiation, 196–197
 carcinogenesis, 201–205
 deterministic events, 197–198
 genetic effects, 208
 immunosuppression, 209–210
 injuries from, 196, 240–242
 regulatory guides for exposure, 210
 somatic cell effects, 198–201
 sources of, 197
 stochastic events, 197–198
 transgenerational effects, 208–209
 in utero effects, 205–208
 Iridium-192, 11
 Isotopes. *See* Radionuclide internal contamination

J

Just-in-time training, 187–188

K

Karyotype, human, 270
 Keratinocyte growth factor, 30
 Kinetic energy, 2

L

LD₅₀
 blast effects and, 6–7
 effect of clinical support on dose effect curve, 22
 influence of trauma, 21–22
 radiation lethality curve, 21

Lethal dose. *See* LD₅₀
Lethality curve, radiation, 21
Lethality studies, 206
Leukemia, 203–204
Linear-no-threshold dose response, 129
Los Alamos National Laboratory, New Mexico, 22–25, 129
Lung cancer, 205
Lymphocyte cell cycle, 268–270
Lymphocyte count depression, 61

M

Magnetic resonance imaging, 134–135
Male sterility, 199
Mass defect, 3
Measurements, radiation, 43, 220–221
Medical Communications for Combat Casualty, 106
Medical radiation exposure, 128, 130–131
Medical recording, 104–106
Medical treatment facilities
 decontamination management, 65
 field facilities, 235–236
 higher level facilities, 236
 mass casualty treatment, 55
 patient decontamination sites, 233–235
Medical Treatment Protocols for Radiation Accident Victims, 104–105, 120–124
Medics
 long-term health risks, 54
 personal protection, 53–54
Mega electron volts, 5
Mental health. *See* Psychological issues
Metabolomic biomarkers, 111–112
Metronidazole, 92
MEV. *See* Mega electron volts
Military personnel
 long-term health risks, 54
 personal protection, 53–54
 predicting radiation-induced changes in performance, 131–133
 psychological effects, 66–67
 psychological issues, 181
 triage system, 54–55
Mission-oriented protective posture level 4, 53
Mobilizing agents, 77
MOD. *See* Multiorgan dysfunction
MOF. *See* Multiorgan failure
MOPP 4. *See* Mission-oriented protective posture level 4
MRI. *See* Magnetic resonance imaging
MTFs. *See* Medical treatment facilities
Multiorgan dysfunction, 18, 245–246
Multiorgan failure, 18

N

Nagasaki, Japan
 destruction patterns after nuclear detonation, 45–46
National Academy of Sciences
 Biological Effects of Ionizing Radiation report, 54
National Cancer Institute
 radiation event medical management website, 28
National Council on Radiation Protection, 210
National Council on Radiation Protection and Measurements, 185, 227, 230
National Guard Weapons of Mass Destruction Civil Support Teams, 230
National Library of Medicine
 radiation event medical management website, 28
National Planning Scenario No. 1, 51
National Response Framework, 174

NATO. *See* North Atlantic Treaty Organization
Naturalistic behaviors, 138
Nausea
 incidence as function of radiation dose, 19
NCRP. *See* National Council on Radiation Protection
Nervous system. *See* Central nervous system
Neural stem cell transplants, 149
Neurochemistry, 147–148
Neurovascular syndrome, 21, 245
Neurovascular system
 biodosimetry grading system, 125
Neutron bombs, 4–5
Neutrons, 219–220
Neutropenia, radiation-induced, 26, 85
Nitric oxide activity, 146
No-go zones, 232
Norepinephrine, 147
North Atlantic Treaty Organization, 54
North Korea, 173
Nuclear accidents. *See* Radiation accidents
Nuclear binding energy, 3
Nuclear energy
 overview, 2–4
Nuclear reactor incidents, 224–225
Nuclear weapons
 acute radiation syndrome, 14
 blast effects, 5–7, 41–42
 burn injuries, 7–8
 casualty estimates *versus* weapon yield by mechanism of injury, 40
 combined injuries, 14
 damage zones, 232–233
 detonations, 225–226
 direct blast wave peak overpressure, 41–42
 energy distribution, 5
 energy release in, 4–5
 eye injuries, 8
 fallout effects, 8–10
 flame burns, 42
 flash burns, 42
 incidents without nuclear detonation, 225
 indirect blast wind force, 42
 initial and residual radiation effects, 8
 medical consequences of, 11–14
 medical effects of, 41–45
 psychological effects, 173–188
 radiation injuries, 13
 radiation units and measurements, 43
 range of effects, 5
 thermal effects, 5–6, 7–8, 42
 types of, 40–41
 types of ionizing radiation after a nuclear detonation, 43
 whole-body radiation dose-effect relationship, 44
Nutraceuticals, 251–252

O

OEG. *See* Operational exposure guidance
Olfactory function, 138
Operational exposure guidance, 227
Opioids, 148
Organogenesis, 206
Oxazolidinones, 93

P

Paired-pulse facilitation, 140
Penicillins, 92
Perceptual processes, 137–138

Personal dosimeters, 186
 Personal protective equipment, 231, 234–237
 Plutonium-238, 11
 Polymicrobial infections, 88
 Posttraumatic stress disorder, 184
 Potential energy, 2
 PPE. *See* Personal protective equipment
 PPF. *See* Paired-pulse facilitation
 Prebriefing, 187
 Prenatal radiation exposure, 205–208
 Proportional counters, 226
 Proteomic biomarkers, 111–112
 Providence, Rhode Island radiation accident, 129
 Psychological issues
 chronic stress, 178–179
 common stress reactions, 182
 emergency response personnel, 180–181
 fatalism, 177–178
 fear of radiation, 178
 helping behavior in disaster, 176–177
 identifying groups at greater risk, 186–187
 improvised nuclear device impact, 173–174
 individual detection and recording devices, 186
 military personnel, 66–67, 181
 myth of widespread panic, 176
 nuclear proliferation, 173
 nuclear threats and, 66–67, 172–178
 overwhelming of healthcare facilities, 178–179
 population flight, 178
 practicing drills and exercises, 185–186
 preventing and reducing impacts of attacks, 185–188
 radiological weapons, 174
 risk-communication issues, 185, 187–188
 service delivery, 187
 social stigma, 179–180
 spectrum of impacts, 181–185
 terrorism, 173
 PTSD. *See* Posttraumatic stress disorder

Q

Quinolones, 92

R

RADIAC meters, 43, 53

Radiation. *See also* Ionizing radiation
 clinical irradiation, 130–131
 cognitive performance and, 138–139
 contamination surveys, 228–230
 conversions, 220
 detection equipment, 43, 76, 186, 226–227
 distribution of background radiation, 128
 event medical management website, 28
 fundamentals of, 218–223
 initial and residual effects, 8
 interaction with other environmental factors, 144–145
 linear-no-threshold dose response, 129
 naturalistic behaviors and, 138
 perceptual changes and, 137–138
 predicting radiation-induced changes in military performance,
 131–133
 quality factors, 221
 relative tissue sensitivity, 131
 sensory processes and, 137–138
 sources of exposure, 128
 in space, 137
 terms, 220–221
 types of, 219–220

types of ionizing radiation after a nuclear detonation, 43
 typical doses received in the U.S., 44
 units and measurements, 43, 220–221
 whole-body radiation dose-effect relationship, 44
 Radiation accidents
 Chernobyl nuclear reactor accident, 12–13, 130, 183, 224–225
 Fukushima Daiichi, Japan nuclear power plant, 224
 Goiânia, Brazil incident, 178, 180
 Los Alamos National Laboratory, New Mexico, 22–25, 129
 Three Mile Island Nuclear Power Plant, Pennsylvania, 178–179
 Radiation bioassays, 102
 Radiation detection, indication, and computation meters, 43, 53
 Radiation dose. *See also* Biological dosimetry
 body location record, 106
 carcinogenesis and, 205
 clinical assessment, 60–61
 contamination surveys, 228–230
 cytogenetic studies, 62
 decontamination sites, 233–235
 dose rate, 137
 early performance decrements and, 137
 effects of medical care levels on risk of death, 102
 emergency limits, 228
 estimates of time to vomiting after whole-body dose, 60
 exposure limits for workers, 227–228
 incidence of nausea and emesis as function of dose, 19
 laboratory assessment, 61–62
 lymphocyte count depression, 61
 radiation control zones, 230
 recommended limits, 210
 regulatory limits, 228
 search and rescue personnel, 230–232
 triage dose prediction, 275–276
 Radiation Emergency Assistance Center/Training Site, 18, 60
 Radiation-induced fibrosis, 198–199
 Radiation-induced immunosuppression, 209–210
 Radiation injuries. *See also* Acute radiation syndrome; Bacterial
 infections; Behavioral radiation effects
 animal studies, 136–139
 background radiation, 196–197
 biological damage, 242
 brain damage, 133–134, 136, 139–145
 carcinogenesis, 201–205
 cataract formation, 198
 cellular models, 146–147
 chromosome aberrations, 271–272
 clinical manifestations, 44–45
 cutaneous syndrome, 64
 definitive treatment, 62–64
 deleterious effects of radiation, 211
 epilation, 49
 gastrointestinal syndrome, 20–21, 244–245
 genetic effects, 208
 hematopoietic syndrome, 19–20, 62–63, 243–244
 human database, 202–203
 hyperexcitability, 144
 immunosuppression, 209–210
 infectious complications, 63–64
 inflammation, 148–149
 ionizing radiation, 196, 240–242
 latent central nervous system radiation, 134–135
 multiorgan dysfunction, 18, 245–246
 nervous system pathology, 145–146
 neurovascular subsyndrome, 21, 245
 nuclear weapons and, 13
 oropharyngeal lesions, 49
 psychological effects, 66–67, 172–188
 purpura, 49

- radiation doses resulting in classic syndromes, 45
 - radiation units and measurements, 43
 - skin damage, 199–201
 - sterility, 199
 - therapeutic targets, 147–149
 - tissue fibrosis, 198–199
 - transgenerational effects, 208–209
 - triage, 57
 - types of, 243–246
 - types of delayed effects, 196
 - types of ionizing radiation after a nuclear detonation, 43
 - in utero effects, 205–208
 - whole-body radiation dose-effect relationship, 44
- Radiation lethality curve, 21
- Radiation protection
- aminothiols, 250–251
 - antiapoptotic mechanisms, 248–249
 - antioxidants, 251–252
 - biological response modifiers, 253–255
 - characteristics of countermeasures, 246
 - chemical repair by hydrogen transfer, 247–248
 - combination agents, 255–257
 - contamination control, 222–223
 - countermeasures, 250–257
 - cytokines, 253–255
 - distance and, 222
 - eicosanoids, 252–253
 - endogenous antioxidant systems, 251–252
 - first responder protection, 240
 - genetic repair, 248
 - hypoxia, 246–247
 - immunomodulators, 253–255
 - as low as reasonable achievable concept, 221–222
 - mechanisms, 246–250
 - medical management of events, 240
 - nutraceuticals, 251–252
 - pharmacological side effects, 258
 - radiation countermeasure agents, 241–242
 - regeneration, 249–250
 - regimen development, 257–258
 - scavenging, 247
 - shielding, 222
 - single agents, 250–255
 - supportive therapy, 250, 256–257
 - systems biology approach, 258
 - thiol derivatives, 250–251
 - time factor, 222
- Radiation syndrome. *See* Acute radiation syndrome
- Radioisotopes, 220
- Radiological dispersal devices, 11, 41, 174–175, 224
- Radiological exposure devices, 223–224
- Radiological weapons
- dispersal devices, 11
 - exposure devices, 10
 - potential radioactive sources, 11
 - psychological effects, 174
 - types of, 40–41
- Radionuclide internal contamination
- assessing contaminated personnel, 75–76
 - blocking agents treatment, 77
 - body location record, 106
 - chelating agents treatment, 77–79
 - diluting agents treatment, 77
 - evaluating contaminated patients, 76
 - initial determination, 76
 - isotopes of concern, 75
 - mobilizing agents treatment, 77
 - normal clearance mechanisms, 74–75
 - routes of exposure, 74–75
 - treating contaminated wounds, 79
 - treatment decisions, 76
 - treatment of, 77–79
 - treatment options, 78
 - uptake-reducing agents treatment, 77
- Radionuclides, 220
- RDDs. *See* Radiological dispersal devices
- REAC/TS. *See* Radiation Emergency Assistance Center/Training Site
- Reactive oxygen species, 146, 242
- RED. *See* Radiological exposure devices
- Regeneration, 249–250
- Residual radiation, 8
- Respiratory system
- radiation biomarkers and functional tests, 110–111
- RIF. *See* Radiation-induced fibrosis
- S**
- SALT triage system, 54–55
- Scavenging, 247
- SCBA. *See* Self-contained breathing apparatus
- Scintillation counters, 226
- SED. *See* Skin erythema dose
- Self-contained breathing apparatus, 231–232
- Sensory processes, 137–138
- Sepsis, 87–88
- Seven-ten rule, 9
- Shielding, 149
- Simple triage and rapid treatment, 54
- Skin cancer, 200, 205
- Skin damage, 199–201
- Skin erythema dose, 200
- Social stigma, 179–180
- Sodium ions, 147
- Somatic cells
- ionizing radiation effects, 198–201
- Sort, assess, lifesaving interventions, treatment and /or transport, 54–55
- Space radiation, 137, 142–144
- START triage system, 54
- Sterility, 199
- Strategic National Stockpile Radiation Working Group, 18, 28, 58
- Streptogramins, 93
- Strontium-90, 11
- Supportive therapy, 250, 256–257
- T**
- Teratogenesis, 206, 207
- Terrorism
- psychological effects, 173–178
- Thermal effects, nuclear weapons, 5–6, 7–8, 42
- Thermoluminescent dosimeters, 226–227
- Thermonuclear weapons, 4
- Thiol derivatives, 250–251
- Threat Reduction Agency, 230
- Three Mile Island Nuclear Power Plant, Pennsylvania, 178–179
- Thrombocytopenia, 85
- Thyroid cancer, 204
- Tissue fibrosis, 198–199
- TNT. *See* Trinitrotoluene
- Transgenerational radiation effects, 208–209
- Triage
- biological dosimetry diagnostic approaches, 109–112
 - combined-injury triage, 57–59
 - conventional-injury triage, 55–57
 - DIME system, 54–55

dose prediction, 275–276
of mass casualties, 55
radiation-injury triage, 57
U.S. military system, 54–55
Trinitrotoluene, 2, 225

U

U-235 fission
probability curve for production of radioisotopes, 9
United Nations Security Council, 173
United Nuclear Fuels Recovery Plant, 23
Units, radiation, 43, 220–221
Uptake-reducing agents, 77
Uranium-235 recovery plant accident, 129
Urban casualties
current projections for ground-level nuclear detonation, 51–53
evacuation assets, 59
Hiroshima detonation, 45–51
resource resupply, 59–60
U.S. Department of Defense
National Response Framework, 174
Threat Reduction Agency, 230
U.S. Department of Health and Human Services
radiation event medical management Web site, 28
U.S. Department of Homeland Security
Interagency Modeling and Atmospheric Advisory Center, 230
National Planning Scenario No. 1, 51
U.S. Environmental Protection Agency, 227
U.S. Food and Drug Administration, 84

V

Vaccines, antimicrobial, 94–95
Vancomycin, 92–93
Vestibular function, 138
Viral infections, 89
Vision, radiation effects, 137–138
Vomiting
estimates of time after whole-body radiation dose, 60

W

Weapons of Mass Destruction Civil Support Teams, 230
Wind force, indirect blast effects, 42
Wood River Junction, Rhode Island, 25

X

X-rays, 219

